Gland Pharma Share Price: Investors ki hui Lottery! Q3 mein Profit aur Revenue dono zabardast badhe

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Gland Pharma Share Price: Investors ki hui Lottery! Q3 mein Profit aur Revenue dono zabardast badhe
Overview

Arre bhai Gland Pharma ke results aa gaye hain aur number ekdum solid hain! Quarter 3 mein company ka consolidated revenue **22%** saal-dar-saal badh kar **₹16,954 million** ho gaya hai. Aur suno, adjusted EBITDA toh **25%** chadh gaya, matlab **₹4,490 million** ki kamaai, aur margin bhi **26%** pakka ho gaya! Sabse badhiya baat, European subsidiary Cenexi bhi finally profitable ho gayi hai.

Okay, toh numbers toh mast hain hi, par aur bhi bahut kuch hai sunne layak!

📈 Numbers Ka Full Scene!

Gland Pharma ne Q3 FY26 mein dhamakedaar performance di hai. Unka consolidated revenue 22% saal-dar-saal badhkar ₹16,954 million tak pahunch gaya. Aur EBITDA toh usse bhi zyada, 25% upar, matlab ₹4,490 million! Isse company ka EBITDA margin bhi 26% ho gaya hai, jo pichle saal se kaafi accha hai.

Pehle 9 mahine (9M FY26) ki baat karein toh revenue ₹46,879 million raha, jo 12% saal-dar-saal growth hai. Aur issi period mein EBITDA margin bhi sudhar kar 25% ho gaya hai, matlab company kaafi efficiently kaam kar rahi hai.

🇪🇺 Europe Ka Star Player: Cenexi!

Sabse badi khabar ye hai ki Gland Pharma ki European subsidiary, Cenexi, finally profitable ho gayi hai! Pichle kuch time se struggle kar rahi thi, par Q3 FY26 mein isne ₹148 million (EUR 1.4 million) ka positive EBITDA report kiya hai. Ye ekdum management ke guidance ke hisaab se hai aur group ki profitability mein bada contribution dega. Isse pata chalta hai ki Gland Pharma apne international operations ko bhi sambhal sakti hai.

Company ka operating cash flow bhi zabardast raha ₹6,269 million (9M FY26) ka, matlab business se cash accha ban raha hai. Capex bhi ₹3,566 million kiya hai.

🚀 Future Ka Plan Kya Hai?

Company management future ko lekar bahut confident hai. New products launch karne ki planning hai, CDMO contracts badh rahe hain, aur nayi capacities bhi aa rahi hain.

Sabse bada strategic move hai ₹2,000 crore ka capital expenditure (capex) jo aage wale 5 saal mein hone wala hai. Ye paisa Blow-Fill-Seal (BFS) aur ophthalmic lines ki capacity badhane mein lagega, aur CDMO contracts ke liye bhi use hoga. Isse company ka gross block double ho jayega!

R&D pe bhi kharcha badhaya hai, ab 5.4% revenue ka iss quarter mein. Complex injectables aur advanced delivery systems par focus hai. US mein 9 ANDAs file kiye hain aur 10 naye products launch kiye hain. Goal hai ki company high-end, innovation-led CDMO aur specialty injectables banaye aur aage wale 5 saal mein 15% CAGR ki organic growth achieve kare.

🚩 Risks Aur Outlook

Sab kuch accha lag raha hai, par investors ko dhyaan dena hoga ki ye jo ₹2,000 crore ka ambitious capex plan hai, uska execution kaise hota hai. Agar koi delay ya cost badhi, toh profit pe asar pad sakta hai. CDMO aur specialty injectables market kaafi competitive hai, isliye innovation aur capacity utilisation critical hoga. US mein Liraglutide launch hone wala hai, Europe approval ke baad, jo ek important event hoga. Company ka 15% CAGR target achieve karne ke liye CDMO partnerships badhana aur capacity ka poora fayda uthana bahut zaroori hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.